Research and Markets (http://www.researchandmarkets.com/research/rnnlmg/skin) has announced the addition of the "Skin Cancer-Pipeline Insights, 2016" report to their offering.

Skin Cancer-Pipeline Insights, 2016 provides in depth insights on the pipeline drugs and their development activities around the Skin Cancer. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.

Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.

The report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Skin Cancer.

The report also assesses the Skin Cancer therapeutics by Monotherapy, Combination products, molecule type and Route of Administration.

Scope

  • The report provides competitive pipeline landscape of Skin Cancer
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Skin Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Skin Cancer and also provide company profiling
  • The report also gives the information of dormant and discontinued pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Key Topics Covered:

  1. Skin Cancer Overview
  2. Skin Cancer Pipeline Therapeutics
  3. Skin Cancer Therapeutics under Development by Companies
  4. Skin Cancer Filed and Phase III Products
  5. Comparative Analysis
  6. Skin Cancer Phase II Products
  7. Skin Cancer Phase I and IND Filed Products
  8. Skin Cancer Discovery and Pre-Clinical Stage Products
  9. Skin Cancer - Therapeutics Assessment
  10. Assessment by Monotherapy Products
  11. Assessment by Combination Products
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Skin Cancer - Discontinued Products
  15. Skin Cancer - Dormant Products
  16. Companies Involved in Therapeutics Development for Skin Cancer

For more information visit http://www.researchandmarkets.com/research/rnnlmg/skin